Skip to main content

Month: August 2020

TOMI Environmental Solutions, Inc. Reports Second Quarter 2020 Financial Results

BEVERLY HILLS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (OTCQB:TOMZ), is a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products – a hydrogen peroxide-based mist and fog comprised of ionized Hydrogen Peroxide (iHP), announced its results for the second quarter of 2020.  TOMI Chief Executive Officer, Dr. Halden Shane stated, “We experienced sustained growth in the second quarter and hit a major milestone with revenues exceeding $10 million as a result of strong global demand for innovative technologies in disinfection and infectious disease control.  With the increase in sales to date and the foreseeable future, a second manufacturer was added to expand our production...

Continue reading

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen® for Vascular Repair

A Hybrid Approach for Vascular Control and Repair of an Expanding Iatrogenic Femoral Artery PseudoaneurysmJ. Gorecka, J.F Chen, S. Shah, A. Dardik, R.J Guzman, N. Nassiri, Journal of Vascular Surgery Cases and Innovative Techniques (July 18, 2020), doi: https://doi.org/10.1016/j.jvscit.2020.07.010MIRAMAR, Fla., Aug. 13, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is pleased to  announce that physicians at Yale University School of Medicine and the VA Connecticut Healthcare System have published a paper in the Journal of Vascular Surgery Cases and Innovative Techniques describing the use of Excellagen® wound conforming collagen matrix as part of a hybrid surgical protocol to repair a femoral artery pseudoaneurysm. Femoral artery pseudoaneurysms are the most common complication following...

Continue reading

Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

SEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the second quarter ended June 30, 2020, and provided an update on recent company developments.  Key recent developments included:Received approval from the Australian Human Research Ethics Committee (HREC) to open a Phase 1 clinical study in Australia using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. As of August 3, 2020, all necessary approvals were obtained and enrollment is expected to begin in the coming weeks. Contracted with Avance Clinical Pty. Ltd. to conduct a clinical study of Atossa’s...

Continue reading

US Biosimilars Market Size to Reach $22,996 Million by 2027; Recent Scientific Discoveries Have Indicated Signs of a Promising Future, says Fortune Business Insights™

Pune, Aug. 13, 2020 (GLOBE NEWSWIRE) — The US Biosimilars Market size is projected to reach USD 22,966 million by the end of 2027. The presence of several large scale companies that are engaged in the research and development of efficient biosimilars will have a huge impact on the growth of the overall market in the foreseeable future.According to a report published by Fortune Business Insights, titled “US Biosimilars Market Share, Size & COVID-19 Impact Analysis, By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies and Others), By Disease Indication (Caner, Auto Immune Diseases (Arthritis, Psoriasis, Neutropenia, and others), and Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy),” the market was worth USD 737.2 million in 2019 and will exhibit a CAGR of 46.2% during the...

Continue reading

Kelso Technologies Inc. Financial Results for the Six Months Ended June 30, 2020

VANCOUVER, British Columbia and BONHAM, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) — Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) reports that the Company has released the unaudited interim consolidated financial statements and Management Discussion and Analysis for the three and six months ended June 30, 2020.The unaudited interim consolidated financial statements were prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). All amounts herein are expressed in United States dollars (the Company’s functional currency) unless otherwise indicated.SUMMARY OF FINANCIAL PERFORMANCELIQUIDITY AND CAPITAL RESOURCESAt June 30, 2020 the Company had cash on deposit in the amount of $3,374,304, accounts receivable of...

Continue reading

ShiftPixy Labs Announces Ghost Kitchen Incubator Contest

IRVINE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — ShiftPixy, Inc. (NASDAQ: PIXY), a California-based gig engagement platform provider, today revealed its new contest program as part of the ShiftPixy Labs Ghost Kitchen Incubator Project. As an addition to the Company’s thrilling new Ghost Kitchen expansion, the contest will offer qualified chefs and restaurant operators the chance to earn a spot in the Incubator by pitching and testing new ideas with fully simulated ghost kitchen and delivery experiences. The contest as well as the Incubator Project will be streamed on YouTube, providing the Company and all participants with an elevated platform for a global audience.With the restaurant industry experiencing a seismic shift towards ghost kitchens and delivery-centric business models, it’s more important than ever for operators to...

Continue reading

Philips launches Rapid Equipment Deployment Kit to COVID-19 response

August 13, 2020New initiative can provide critical care patient monitoring anywhere, anytime to help meet the urgent challenges of ICU capacityHelps mitigate the impact of natural disasters and pandemics like the ongoing COVID-19 outbreakAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced its Rapid Equipment Deployment Kit for ICU ramp-ups, allowing doctors, nurses, technicians and hospital staff to quickly support critical care patient monitoring capabilities during the COVID-19 pandemic.  Currently successfully in use in the first health systems across the US [1], the Rapid Equipment Deployment Kit combines Philips advanced patient monitoring technology with predictive patient centric algorithms enabling  care teams to quickly scale up critical care patient monitoring...

Continue reading

Genius Brands International Issues CEO Newsletter

BEVERLY HILLS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — Genius Brands International, Inc. “Genius Brands” (GNUS), the global brand management company that creates and licenses multimedia entertainment content for children, released a letter to shareholders from Chairman & CEO Andy Heyward. The complete letter follows:Dear Friends and Shareholders, SpongeBob SquarePants, in my opinion, is the most clever and well-written children’s series of the last 20 years. I share this because at Genius Brands (NASDAQ:GNUS)

Continue reading

Edison Nation Announces Its Second Quarter 2020 Earnings Conference Call

Bethlehem, PA, Aug. 13, 2020 (GLOBE NEWSWIRE) — Edison Nation, Inc. is pleased to announce that it will hold its Second Quarter 2020 Earnings Conference Call on Thursday, August 20, 2020 at 4:30 pm Eastern Time, which will be presented by Mr. Christopher Ferguson – Chief Executive Officer, and Mr. Brett Vroman – Chief Financial Officer. The Company will report its Second Quarter 2020 Earnings on or before Monday, August 17, 2020.The Company encourages shareholders to submit questions to the Company at shareholders@edisonnation.com by 5:00 pm Eastern Time on Tuesday, August 18, 2020. The Company’s management will gladly answer as many questions as possible within the time allotted.The conference call can be accessed through the following numbers:1-877-407-0782 (U.S. participants)1-201-689-8567 (International participants)To...

Continue reading

PyroGenesis Provides Updated EPS Guidance for Third Quarter and Full Year 2020

MONTREAL, Aug. 13, 2020 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch systems, is pleased to provide today, further to its Q2 2020 financial press release dated July 29th, 2020, updated earnings per share (“EPS”) guidance for Q3 2020, and the full year 2020.PyroGenesis now expects EPS for Q3 2020 to be in excess of $0.07. On July 29th, 2020, the Company had given prior guidance of $0.06 for the same period. Furthermore, the Company now expects an EPS for the full year 2020 to be conservatively in excess of $0.11.“We understand the market’s interest...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.